FDA sends Hikma back to the clinic with generic Advair
admin 13th March 2018 Uncategorised 0GlaxoSmithKline just keeps racking up the victories in the generic Advair department. Partners Hikma and Vectura have officially wrapped up their dispute with the FDA, and not in a good way. The agency is sending the pair back to the drawing board with a request for an additional clinical endpoint study.
More: FDA sends Hikma back to the clinic with generic Advair
Source: fierce